Lucid Diagnostics Secures Broad Commercial Coverage for EsoGuard Esophageal DNA Test
Event summary
- Concert issued a positive coverage policy for EsoGuard® effective July 2026, citing strong clinical evidence and improved health outcomes.
- Multiple Concert client health plans have already adopted the coverage policy.
- EsoGuard is recognized as medically necessary for patients meeting American College of Gastroenterology (ACG) screening criteria.
The big picture
This coverage policy marks a critical milestone in Lucid's efforts to broaden commercial access for its EsoGuard test, leveraging Concert's influence over multiple health plans. The move aligns with broader industry trends toward early cancer detection and prevention, particularly for high-risk patient populations like those with GERD. Lucid's ability to secure this policy underscores the growing recognition of non-invasive diagnostic tools in improving health outcomes.
What we're watching
- Adoption Pace
- How quickly additional health plans will adopt the coverage policy and expand access to EsoGuard.
- Clinical Validation
- Whether ongoing engagement with commercial insurers will further strengthen the clinical evidence base.
- Market Penetration
- The pace at which Lucid can scale EsoGuard adoption among at-risk GERD patients nationwide.